We have previously reported that astrocyte elevated gene-1 (AEG-1) was upregulated in human breast cancer. However, the biological function of AEG-1 in the development and progression of breast cancer remains to be clarified. In this study, we examined the effect of AEG-1 on cell proliferation and found that AEG-1 upregulation was significantly linked to increased Ki67 (Po0.001). Ectopic expression of AEG-1 in MCF-7 and MDA-MB-435 breast cancer cells dramatically enhanced cell proliferation and their ability of anchorage-independent growth, whereas silencing endogenous AEG-1 with shRNAs inhibited cell proliferation and colony-forming ability of the cells on soft agar. Furthermore, these proliferative effects were significantly associated with decreases of p27 Kip1 and p21
Introduction
Oncogenesis is a complex multi-step process, characterized by progressive accumulation of genetic and epigenetic alterations, ultimately leading to uncontrolled cell growth and tumor formation. Although propagation of normal cells is under strict control by elaborate regulation of proliferation and death, during oncogenesis cells proliferate in a progressive, deregulated manner. Uncontrolled cell growth is largely associated with alternations in genes or proteins related to regulation of proliferation, cell death and genetic stability, such as tumor suppressor genes, oncogenes, growth factors and cell adhesion molecules, which vary among different cancer types (Doerfler et al., 2001; Trent, 2006) . Identification of genes and their products involved in the molecular events leading to oncogenesis is the key to development of effective therapeutic strategies and diagnostic and prognostic methods for cancers.
Recently, a newly identified astrocyte elevated gene-1 (AEG-1), originally discovered as a protein induced in primary human fetal astrocytes infected with HIV-1 or treated with HIV gp120 or tumor necrosis factor-a, was implicated in promotion of oncogenesis, abrogation of cancer cell apoptosis and induction of metastasis (Kang et al., 2005; Emdad et al., 2006 Emdad et al., , 2007 Lee et al., 2006 Lee et al., , 2008 Kikuno et al., 2007; Ash et al., 2008; Li et al., 2008; Sarkar et al., 2008) . It was found that ectopic expression of AEG-1 could augment anchorage-independent growth of nontumorigenic melanocytes and astrocytes (Kang et al., 2005; Emdad et al., 2007) . Furthermore, overexpression of AEG-1 was shown to inhibit apoptosis induced by serum starvation in immortalized primary human fetal astrocytes, whereas AEG-1 knockdown reduced cell viability and promoted apoptosis in prostate cancer cells (Kikuno et al., 2007; Lee et al., 2008) . In addition, the oncogenic function of AEG-1 was further demonstrated by the finding that AEG-1 could promote proteasomal degradation of tumor suppressor BCCIPa, which participates in regulation of cell cycle, maintenance of genomic integrity and inhibition of centrosome amplification (Liu et al., 2001; Meng et al., 2004 Meng et al., , 2007 Ash et al., 2008) . It is of note that the oncogenic feature of AEG-1 was associated with tumor development or progression in experimental as well as clinical settings. Upregulation of AEG-1 increased, and downregulation of AEG-1 decreased, lung metastasis of breast cancer cells (Brown and Ruoslahti, 2004) . Overexpression of AEG-1 could lead to increased migration and invasion of gliomas cells, whereas depletion of endogenous AEG-1 in gliomas cells significantly inhibited their migration and invasion Sarkar et al., 2008) . All these studies suggest that AEG-1 may play important roles in the oncogenesis of several malignancies. In fact, the expression level of AEG-1 is frequently upregulated in various human tumor types, including breast cancer, multiform glioblastoma, melanoma and prostate cancer (Kang et al., 2005; Emdad et al., 2007; Kikuno et al., 2007; Li et al., 2008) .
The molecular mechanisms by which AEG-1 mediates oncogenesis have been linked to activation of nuclear factor-kB (NF-kB) and to the PI3K/Akt signaling pathway. Emdad et al. reported that the transcriptional activity of NF-kB could be markedly induced by ectopically expressing AEG-1, and it was suggested by the same group that AEG-1 might act as a bridging factor to link NF-kB to the cyclic AMP responsive element binding protein (CBP) as well as other transcriptional activators by forming basal transcription machinery Sarkar et al., 2008) . Kikuno et al. reported that silencing endogenous AEG-1 could inhibit the progression of prostate cancer through suppressing Akt activity, in consistence with the finding made by Lee et al . that upregulation of AEG-1 inhibited serum starvation-induced apoptosis via activation of PI3K/Akt signaling (Kikuno et al., 2007; Lee et al., 2008) .
Our previous study found that expression of AEG-1 was correlated with the clinical staging and tumor-nodemetastasis (TNM) classification of breast cancer (Li et al., 2008) . This study investigated the potential role of AEG-1 in the regulation of breast cancer cell proliferation. Here we report that upregulation of AEG-1 is significantly associated with cell proliferation marker Ki67 (Po0.001) as demonstrated by clinicopathological analysis. Deregulation of AEG-1 expression was found to be closely linked to proliferation and tumorigenicity of breast cancer cells. We also demonstrated that AEG-1 could downregulate the FOXO1 level by inducing FOXO1 phosphorylation via the PI3K/Akt pathway, consequently reducing the expression of cyclin-dependent kinase (CDK) inhibitors, p27
Kip1 and p21
Cip1
.
Results

AEG-1 is overexpressed in highly proliferative breast cancer
We recently reported that AEG-1 was highly expressed in breast cancer cell lines and primary breast tumors. To further investigate the biological role of AEG-1 in breast cancer progression, expression of proliferative marker Ki67 was determined in previously reported 225 archived breast cancer tissues using immunohistochemical (IHC) staining, and correlation study was performed between the expression level of AEG-1 and that of Ki67. As shown in Figure 1 , section areas that presented high level of AEG-1 showed strong staining signal of Ki67, and those with low AEG-1 expression displayed weakly detectable Ki67. Statistical analyses revealed that the correlation between AEG-1 and Ki67 expression was significant (P ¼ 0.003; Supplementary Table 2 ). These results suggest that AEG-1 is vastly expressed in highly proliferative human breast cancer cells, in consistence with our earlier notion that AEG-1 upregulation is associated with the progression of breast cancer and correlated with the poor prognosis of the disease.
Upregulation of AEG-1 promotes proliferation and tumorigenicity of breast cancer cells As the expression level of AEG-1 was found to strongly correlate with the proliferative status of breast cancer tissue, we hypothesized that upregulating AEG-1 expression might promote the growth of breast cancer cells. Indeed, when two breast cancer cell lines, MCF-7 and MDA-MB-435, were established to stably express ectopic AEG-1 (Figure 2A ), the AEG-1 overexpressing MCF-7 and MDA-MB-435 cells displayed significantly higher growth rates by approximately twofold as compared with the control cells at day 4 after plating (Po0.05; Figure 2B ; Supplementary Figure 1A) . Furthermore, the increase of cell growth by AEG-1 overexpression was also observed in MTT assay and colony formation assay (Supplementary Figures 1B and C) . In addition, as our previous study results showed that AEG-1 level significantly correlated with the clinical staging of the patients with breast cancer, we further examined the effect of AEG-1 on the tumorigenic activity of breast cancer cells using anchorage-independent growth ability assay. As shown in Figure 2C , upregulation of AEG-1 in MCF-7 and MDA-MB-435 cells significantly increased the anchorage-independent growth ability of both breast cancer cell lines as shown as increases in the colony number and colony size (Po0.05), These results suggest that upregulation of AEG-1 in breast cancer cells could result in increase of the tumorigenicity in vitro.
AEG-1 is essential for breast cancer cell proliferation
The above findings indicated that AEG-1 might play a role in the overproliferation phenotype of breast cancer cells. To further demonstrate the significance of the proproliferative function of AEG-1 in breast cancer cells, we employed AEG-1-knocked-down cell model, which was created using specific AEG-1-shRNAs, and examined the rates of cell growth.
As shown in Figure 3A , both shRNAs effectively knocked down the level of endogenous AEG-1 protein in MCF-7 and MDA-MB-435 cells and slowed down the growth of the cells ( Figure 3B ; Supplementary Figures 2B and C). In consistence with these results, depletion of endogenous AEG-1 in MCF-7 and MDA-MB-435 cells also caused significant inhibition of their anchorage-independent growth ability, as indicated by reduction in colony number and colony size on soft agar (Po0.05; Figure 3C ). Together these results suggest that AEG-1 is essential for proliferation in breast cancer cells as well as their tumorigenic phenotype. 
AEG-1 regulates cell-cycle inhibitors p21
Cip1 and p27
Kip1
in breast cancer cells The observed correlation of deregulated AEG-1 expression with proliferation of breast cancer cells prompted us to further investigate the possibility that cell-cycle regulators might be under the modulation by AEG-1. Western blot analysis revealed that expression of ectopic AEG-1 did not affect the expression of CDK2, cyclin A, cyclin B and cyclin E, all of which are cell-cycle promoters. Instead, the expression of two CDK inhibitors, p21 Cip1 and p27
, were dramatically downregulated (Po0.05; Figure 4A ). Moreover, the expression level of phosphorylated pRb was increased in AEG-1-overexpressing cells in comparison with the vector-transduced cells. In contrast, the expression levels of p21
Cip1 and p27 Kip1 in AEG-1-knocked-down breast cancer cells were significantly upregulated compared with those in control cells, and Rb phosphorylation was also shown to be decreased (Po0.05; Figure 4B ). These data confirmed the regulatory role of AEG-1 on cellcycle progression and cell proliferation.
It is well known that CDK inhibitors p21 Cip1 and p27
Kip1 play important roles in the regulation of progression through G 1 to S phase in mammalian cells. To further examine the effect of AEG-1 on cell-cycle progression at the G 1 /S transition, 5-bromo-2-deoxyuridine (BrdUrd) incorporation assay was performed. Cells were synchronized by serum starvation for 48 h and then induced to reenter the cell cycle by the addition of serum (10%) for 4 or 8 h. At 4 h after serum addition, less than 1.0% MCF-7 and MDA-MB-435 cells with AEG-1-knocked-down-incorporated BrdUrd, whereas the S-phase fraction with BrdUrd incorporation significantly increased in MCF-7 (14.6%) and MDA-MB-435 (13.2%) cells ectopically expressing AEG-1, as compared with the vector-infected control cells (6 and 6.3% for MCF-7 and MDA-MB-435 control cells, respectively; Figure 4C ; Supplementary Figure 3) . At 8 h after the addition of serum, approximately 1.7-fold increase in BrdUrd incorporation in AEG-1-infected cells as compared with those in vector-infected control cells (36.2 vs 21.2% for MCF-7 cells and 39.8 vs 23.7% for MDA-MB-435 cells), whereas only 6.30 and 7.69% of AEG-1-RNAi(s)-infected MCF-7 and MDA-MB-435 cells, respectively, showed BrdUrd-positive signals ( Figure 4C; Supplementary Figure 3) . Taken together, these results suggest that the expression level of AEG-1 in breast cancer cells may significantly impact on G 1 /S transitional phase entry, accompanying the changes in cell-cycle inhibitors p21
AEG-1 downregulates FOXO1 transcriptional activity via Akt signaling
To understand at which level AEG-1 is involved in the regulation of p21 Cip1 and p27 Kip1 expression, real-time RT-PCR was performed to examine the mRNA levels of p21
Cip1 and p27 Kip1 in AEG-1-overexpressing, AEG-1-knocked-down and vector control breast cancer cells, and as exhibited in Figure 4D (panel a) upregulation of AEG-1 in MCF-7 and MDA-MB-435 cells was found to decrease the mRNA levels of both p21
Kip1
. In contrast, p21
Cip1 and p27 Kip1 mRNAs were significantly elevated in AEG-1 knocked-down MCF-7 and As transcription factor FOXO1 had previously been found to transcriptionally upregulate p27 Kip1 and to induce p21
Cip1 expression by forming transcriptional complexes with SMAD3 and SMAD4 (Dijkers et al., 2000; Nakamura et al., 2000; Seoane et al., 2004) , we asked whether the changes of p27
Cip1 levels caused by AEG-1 were mediated through FOXO1 modulation. Interestingly, although real-time RT-PCR analysis revealed that neither AEG-1 overexpression nor its knockdown changed the level of total FOXO1 mRNA (data not shown), phosphorylated FOXO1 was significantly increased in AEG-1-overexpressing breast cancer cells as compared with that in the control cells, as shown by western blotting analysis, and a dramatic reduction of phosphorylation of FOXO1 was observed in AEG-1 knocked down cells (Po0.05; Figure 5A ). As phosphorylation of forkhead family members had been previously found to lead to retention of the protein in the cytoplasm, consequently inactivating the transactivating activity (Brunet et al., 1999; Rena et al., 1999; Tang et al., 1999) , we had anticipated that AEG-1 could promote the cytoplasmic translocation of FOXO1. As expected, the cellular fractionation experiment showed that expression of FOXO1 in the nuclei was markedly increased in AEG-1 knocked-down cells and decreased in AEG-1-overexpressing cells (Po0.05; Figure 5B ; Supplementary Figure 4) . Impacts on the transactivation activities of FOXO1 by AEG-1 appear to be a direct effect, because the luciferase activities of a FOXO1 reporter was markedly increased in AEG-1-expressing cells whereas significantly inhibited in AEG-1 knocked-down breast cancer cells (Po0.05; Figure 5C ). Taken together, these results strongly suggest that AEG-1 represses the transcriptional activity of FOXO1 via promoting its cytoplasmic translocation.
It is known that phosphorylation of FOXO1 is mediated through activation of the PI3K/Akt signaling (Cardozo and Pagano, 2004; Huang et al., 2005) . Thus, we further examined whether AEG-1 could activate PI3K/Akt pathway. As shown in Figure 5D , upregulation of AEG-1 indeed increased the phosphorylation of Akt in both MCF-7 and MDA-MB-435 cells, as opposed to the decrease of Akt phosphorylation in AEG-1 RNAi-transduced cells, as compared with the transduction control cells (Po0.05). In parallel, associated with the change of Akt phosphorylation was the Clinical relevance of AEG-1 expression and FOXO1 in human breast cancer We next tested in human breast cancer specimens whether upregulated AEG-1 expression was indeed associated with a downregulation of FOXO1. In our previous study (Li et al., 2008) , IHC staining revealed that high level AEG-1 expression was shown in 100 out of 225 (44.4%) tested breast cancer cases, and 125 cases (55.6%) displayed low AEG-1 expression (Figure 6a) . Notably, we found that 81 out of the 100 (81%) breast cancer samples with high-level AEG-1 expression exhibited low or lack of FOXO1 expression. On the other hand, 86 out of the 125 (68.8%) specimens showed low AEG-1 levels displayed strong FOXO1 staining (Figures 6a and b) . Such an inverse correlation between AEG-1 and FOXO1 expression levels was further confirmed by Spearman's analysis (r ¼ À0.508, Po0.001). Taken together, IHC-staining data further strengthened the notion that AEG-1 mediates proliferation and tumorigenicity of breast cancer through suppression of transactional factor FOXO1.
Discussion
This study has revealed that AEG-1 promotes the proliferation of breast cancer cells, an effect that is associated with downregulation of tumor suppressor and cell-cycle inhibitor genes, p21 Cip1 and p27
Kip1
, possibly via Akt/FOXO1 signaling. We have also demonstrated that accompanied with AEG-1 overexpression in breast cancer is a downregulation of AEG-1 regulates proliferation in human breast cancer J Li et al the FOXO1 protein as compared with normal breast tissue. These findings provide new insights into the potential role of deregulation of AEG-1 in promoting carcinogenesis and progression of breast cancer.
A correlation of AEG-1 with cancer development and progression has recently been demonstrated by studies from several groups, including ours, in which AEG-1 was found to be expressed at high levels in various types of human cancers, including breast cancer, multiform glioblastoma, melanoma and prostate cancer (Kang et al., 2005; Emdad et al., 2006 Emdad et al., , 2007 Lee et al., 2006 Lee et al., , 2008 Kikuno et al., 2007; Ash et al., 2008; Li et al., 2008; Sarkar et al., 2008) . Notably, our previous study also showed a significant correlation of AEG-1 expression with the clinical staging and TNM classification of breast cancer (Li et al., 2008) . In consistence with these clinical findings, at the cellular level it was found that depletion of AEG-1 reduced the viability of prostate cancer cells and subjected cancer cells to apoptosis, and that overexpression of AEG-1 inhibited apoptosis induced by serum starvation (Kikuno et al., 2007; Lee et al., 2008) . It was also demonstrated that upregulation of AEG-1 facilitated metastasis of breast cancer cells to the lung and increased cell migration and invasion, whereas downregulation of AEG-1 could reduce the capabilities of prostate cancer and glioma cells to migrate and to invade (Brown and Ruoslahti, 2004; Emdad et al., 2006; Lee et al., 2008) . Nevertheless, whether AEG-1 also effects on cell proliferation, a key biological event essential for cancer development and progression, largely remains unknown, and we were thus prompted to explore the association between AEG-1 and proliferation of human breast cancer cells.
We first examined the correlation between AEG-1 expression and common proliferating marker Ki67. The significant correlation between AEG-1 and Ki67 expression (P ¼ 0.003) indicates that AEG-1 is overexpressed in highly proliferative lesions of human breast cancer. Further experiments on the effects of AEG-1 overexpression or depletion on cell viability, colony-formation ability and BrdUrd incorporation has provided additional support for the notion that AEG-1 is a proliferation promoting, as the proliferation rate was increased for cells ectopically expressing AEG-1 and robustly decreased for AEG-1-knocked-down cells. In support of these observations, our study also identified effects of AEG-1 on the expression levels of CDK inhibitors p27
Cip1
, two key negative regulators of cell-cycle progression.
FOXO1 is a member of the forkhead box-containing O subfamily (FoxO) family of transcription factors. It has been reported that FOXO1 is involved in regulating a variety of biological processes, such as cell-cycle control, differentiation, stress response and apoptosis (Arden, 2007; Frescas and Pagano, 2008) . It has been demonstrated that FOXO proteins could act as tumor suppressors as evidenced by its transcriptional induction of CDK inhibitors, including p21 Cip1 , p27
Kip1 and p57 kip2 (Nakamura et al., 2000; Seoane et al., 2004; Roeb et al., 2007) . Indeed, FOXO1 expression is downregulated in prostate cancer and endometrial adenocarcinomas (Dong et al., 2006; Ward et al., 2008) . It has been demonstrated that phosphorylation of FOXO (Ser 256 ) by Akt leads to FOXO1 nuclear/ cytoplasmic translocation and subsequent degradation via the ubiquitin-proteasome system (Cardozo and Pagano, 2004; Huang et al., 2005) . Our study also showed that the expression level of FOXO1, an upstream regulator of p27 Kip1 and p21
, was repressed in breast cancer cells expressing high level of AEG-1, whereas it was upregulated in AEG-1 knocked-down breast cancer cells. Furthermore, we demonstrated that downregulation of FOXO1 by AEG-1 is mediated through PI3K/Akt signaling. In addition, IHC data further revealed that FOXO1 protein expression was inversely correlated with AEG-1 overexpression in clinical breast cancer specimens. Thus, this study suggests a novel signaling cascade that links AEG-1 to cell-cycle activation and proliferation, which we believe is important for identifying novel therapeutic targets against breast cancer. How AEG-1 activates the PI3K/Akt pathway is an issue under further investigation in the laboratory. Understanding the precise role played by AEG-1 in breast cancer progression will not only increase our knowledge of the biology of breast cancer but may also enable down- AEG-1 regulates proliferation in human breast cancer J Li et al regulation of AEG-1 to serve as a novel therapeutic strategy in patients.
Materials and methods
Cell lines
Breast cancer cell lines, MCF-7 and MDA-MB-435 were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA) and 100 units of penicillin-streptomycin at 37 1C with 5% CO 2 in a humidified incubator.
Pharmacological inhibitors
Inhibitors of PI3K (LY294002, specific inhibitor of the p110 catalytic subunit of PI3K, cell culture grade; Sigma, St Louis, MO, USA) and Akt (Akt inhibitor X; EMD, La Jolla, CA, USA) were dissolved in Me 2 SO and used at 10 mM, respectively. LY294002 and Akt inhibitor X diluted in normal growth medium were added to medium and incubated for 24 h. (Li et al., 2008) . Clinical and clinicopathologic classification and staging were determined according to the American Joint Committee on Cancer criteria (Greene et al., 2002) .
Immunohistochemistry
The IHC procedure was performed using previously described methods (Li et al., 2008) . The degree of immunostaining of formalin-fixed, paraffin-embedded sections was reviewed and scored independently by two observers, based on both the proportion of positively stained tumor cells and the intensity of staining. The proportion of tumor cells was scored as follows: 0 (no positive tumor cells), 1 (o10% positive tumor cells), 2 (10-50% positive tumor cells) and 3 (>50% positive tumor cells). The intensity of staining was graded according to the following criteria: 0 (no staining); 1 (weak staining ¼ light yellow), 2 (moderate staining ¼ yellow brown) and 3 (strong staining ¼ brown). The staining index (SI) was calculated as staining intensity score Â proportion of positive tumor cells. Using this method of assessment, we evaluated the expression of AEG-1 in benign breast epithelium and malignant lesions by determining the SI, which scored as 0, 1, 2, 3, 4, 6 and 9. Cutoff values for AEG-1 were chosen on the basis of a measurement of heterogeneity with the log-rank test statistical analysis with respect to overall survival. An optimal cutoff value was identified: SI score of X4 was used to define tumors as high AEG-1 expression, and p3 as low expression of AEG-1. The scores of Ki67 and FOXO1 expression were also performed using the above-mentioned method.
Statistical analysis
All statistical analyses were carried out using the SPSS 10.0 statistical software package. The relationship between AEG-1 expression and Ki67 or FOXO1 expression were calculated by Spearman's rank correlation coefficients. Mean±s.d. were calculated, and two-tailed Student's t-test was performed for paired samples using the data analysis tools provided by the software. A Po0.05 in all cases was considered statistically significant.
